Amgen jolts to record-high after hiking FY forecasts, Q2 results beat
BUZZ-Amgen jolts to record-high after hiking FY forecasts, Q2 results beat ** Amgen AMGN.O shares jump 6.5% to all-time high of $415.51 in morning trading
** The stock's previous 52-week high was $398
** The Pharma major late Tuesday reported Q2 revenue of $10.1 billion, easily surpassing Wall Street estimates of $9.42 billion
** Q2 adj. EPS - $6.29 per share; analysts on avg expected $5.62, according to data compiled by LSEG
** AMGN also hiked FY forecasts for profit and revenue
** Results driven by strong sales of Repatha, Evenity and rare disease drugs, while Amgen advances its experimental obesity treatment MariTide
** Including session's move, AMGN stock was up 26% YTD
(Reporting by Padmanabhan Ananthan)
Recent news on Amgen
See all newsUS RESEARCH ROUNDUP-Apple, Kaiser Aluminum, Reliance
Brief: Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer
Corrected: Amgen drug combined with immunotherapy extends survival in lung cancer trial
US RESEARCH ROUNDUP- Amgen, Lockheed Martin, Norfolk Southern
Eli Lilly hits record high as healthcare stocks rally